Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), and Centre for Probe Development and Commercialization (CPDC) announced that Azedra™, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares after opening at $4.02 moved to $4.36 on last trade day and at the end of the day closed at $4.35. Company price to sales ratio in past twelve months was calculated as 21.93 and price to cash ratio as 4.00. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a positive weekly performance of 3.08%.
The top executive of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is in New York to present at a cancer conference, the company has announced. The company stated that its chief executive Linda Powers will be at an annual cancer conference dubbed “ A Long-Awaited Reality.” The presentation happens at New York Academy of Medicine and starts at 2:45 pm ET. The event is convened to help discuss opportunities, challenges and offer platform for players in the cancer immunotherapy to exchange information and showcase their technologies. Thus, the conference brings together executives, analysts and investors. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares advanced 6.22% in last trading session and ended the day on $7.69. NWBO return on equity ratio is recorded as 603.80%. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) yearly performance is 91.29%.
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment. Additional preclinical presentations describe the relationship between ferumoxytol and MM-398 tumor uptake and activity, as well as exploring the mechanistic basis of MM-398 activity across multiple tumor models. Data will be presented in four poster sessions. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares moved up 6.15% in last trading session and was closed at $5.35, while trading in range of $5.05-$5.37. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) year to date performance is 0.38%.
The Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on Mar. 24 provided an overview of its three clinical development programs and financial results for the year ended December 31, 2013. For the year ended December 31, 2013, total operating expenses were $8.0 million. Rexahn’s cash and investments totaled $19.0 million as of December 31, 2013, as compared to $14.7 million on December 31, 2012. The increase of $4.3 million was primarily due to $12.3 million from the issuance of common stock and the exercise of stock warrants and options, offset by $8.0 million of net cash used in operating activities. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is -7.32%. On last trading day company shares ended up $1.14. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average is -2.21%. Analysts mean target price for the company is $2.50.
Leave a Reply